业绩说明会召开情况 - 公司于2025年9月26日下午15:00-16:00通过价值在线平台以网络文字互动方式召开2025年半年度业绩说明会 [1] - 公司董事总经理黄苹、财务总监王永贵、董事会秘书曾庆生及独立董事刘英斌出席会议并与投资者互动交流 [2] - 会议召开公告已于2025年9月20日通过指定媒体及上交所网站披露 [1] 投资者问答内容 - 公司计划通过巩固游戏影视基本盘并挖掘影视产业链、游戏及信息技术服务增长潜力来提升第四季度经营业绩 [3] - 公司将持续加强内部控制监督检查，严防重大风险以推动持续稳健发展 [3] - 公司控股子公司参与出品电视剧《飞到我心上》，具体上线时间需关注相关平台动态 [4] - 控股子公司淘乐网络专注于回合制端游与手游研运一体模式，主要产品包括《桃花源记》端游手游、《桃花源记2》端游、《仙灵逍遥》手游及《少年仙界传》手游 [5] - 淘乐网络将持续优化原有游戏并拓展新合作渠道以提升整体盈利水平 [5] 信息披露渠道 - 本次业绩说明会完整互动交流内容可通过https://eseb.cn/1rGXRZb32OA查看 [6] - 公司对投资者的关注与支持表示衷心感谢 [6]

好的，我将为您分析Cintas公司2026财年第一季度财报电话会议记录，总结关键要点。报告的主要内容如下： - **财务数据和关键指标变化**：公司第一季度总收入增长8.7%至27.2亿美元，有机增长率7.8%，每股收益增长9.1%至1.20美元。[4] - **各条业务线数据和关键指标变化**：三大路由业务均实现强劲增长，其中急救与安全服务增长14.1%，消防服务增长10.3%，制服租赁服务增长7.3%。[8] - **各个市场数据和关键指标变化**：公司通过转换非项目客户和增加现有客户服务实现增长，客户保留率保持高位，客户基础稳定且略有改善。[26][33] - **公司战略和发展方向和行业竞争**：公司继续投资技术、产能和人才，通过SAP实施和技术升级提升效率，专注于将非项目客户转化为服务客户。[5][6][72] - **管理层对经营环境和未来前景的评论**：尽管宏观环境存在不确定性，公司价值主张依然有效，现金流强劲，对2026财年业绩持乐观态度。[4][26][27] - **其他重要信息**：公司提高季度股息15.4%，连续42年增加股息，第一季度股票回购3.474亿美元。[12] - **总结问答环节所有的提问和回答**：分析师关注非项目客户转换、利润率变化、销售周期、关税影响、并购策略和技术投资等方面。[18-125] 接下来，我将为您详细总结财报电话会议的关键要点。 财务数据和关键指标变化 - 第一季度总收入增长87%至272亿美元 有机增长率78% [4] - 毛利率为503% 较去年同期提升20个基点 [4] - 营业利润增长101%至6179亿美元 营业利润率227% 提升30个基点 [4][11] - 有效税率176% 去年同期为158% [11] - 净利润4911亿美元 去年同期452亿美元 [11] - 稀释每股收益120美元 增长91% [4][11] - 经营活动现金流4145亿美元 [11] - 资本支出102亿美元 [12] - 更新2026财年业绩指引：收入预期1106-1118亿美元 总增长率7%-81% 稀释每股收益474-486美元 增长率77%-105% [6] 各条业务线数据和关键指标变化 - 制服租赁设施服务有机增长73% 毛利率497% 较去年提升40个基点 [8][9] - 急救与安全服务有机增长141% 毛利率568% [8][9] - 消防保护服务有机增长103% 毛利率489% [8][9] - 制服直接销售下降92% 毛利率417% [8][9] - 销售和管理费用占收入275% 较去年下降10个基点 [9] 各个市场数据和关键指标变化 - 通过转换非项目客户(do-it-yourselfers)实现增长 成功案例包括西北部交通部门从自购安全背心转向Cintas租赁项目 [7][8] - 向现有客户销售额外处理服务 增加服务渗透率 [7] - 客户保留率保持非常具有吸引力的水平 [26][33] - 客户基础稳定 甚至在本季度略有改善 [26] - 主要垂直市场包括医疗保健、酒店、教育以及州和地方政府 表现均良好 [50] 公司战略和发展方向和行业竞争 - 公司文化被视为最大竞争优势 [4] - 持续投资技术 使员工合作伙伴更容易开展工作 包括促进业务增长和提高效率 [5][6] - 正在消防保护服务业务中实施SAP系统 产生额外成本但对未来持乐观态度 [21][22] - 投资于路由能力、领导力储备、技术、销售资源和管理培训生 [66][69] - 专注于将非项目客户转化为服务客户 而非从竞争对手夺取业务 [72] - 整体市场仍然非常竞争 但公司价值主张持续产生共鸣 [72] 管理层对经营环境和未来前景的评论 - 在多种宏观经济环境下均表现良好 不确定环境可能为公司创造机会 [4][33] - 外包服务帮助客户改善现金流 节省时间 使预算更加可预测 [19] - 尽管就业增长放缓 公司业务仍保持吸引力增长 [33][35] - 对2026财年剩余时间展望反映对战略的信心 [15] - 关税环境动态变化 但公司全球供应链是真正竞争优势 [57][59] - 销售周期保持相当一致 没有真正变化 [60] 其他重要信息 - 宣布季度现金股息增加154% 这标志着连续42年增加股息 自1983年上市以来一直保持这一做法 [12] - 第一季度回购3474亿美元Cintas股票 [12] - 业绩指引假设：2026财年和2025财年工作日数相同 无未来收购 恒定外汇汇率 净利息支出约9700万美元 有效税率200% 无未来股票回购或重大经济中断 [13][14] - 制服直接销售业务具有战略意义 虽然只占收入的26% 但可带来路由业务机会 [77][78] 总结问答环节所有的提问和回答 问题: 宏观经济疲软时转换非项目客户的历史案例 [18] - 在预算压力环境下 公司帮助客户释放现金流 节省时间 使预算更加平滑 公司有信心继续转换非项目客户 [19][20] 问题: 消防业务毛利率下降原因 [21] - SAP实施带来额外成本 公司对该业务未来持乐观态度 正在进行各种投资 包括储备力量、运营能力和技术 [21][22] 问题: 销售环境包括客户预算趋势和销售周期 [26] - 客户行为没有具体变化 销售周期没有改变 在不确定环境中公司价值主张仍然有效 保留率保持高位 客户基础稳定甚至略有改善 [26] 问题: 推动业绩预期上调的业务部分 [27] - 三个路由业务表现都非常好 公司喜欢目前的增长势头 隐含的第二至第四季度增长高于开局指引 [27] 问题: 就业增长放缓对租赁业务净穿着水平的影响 [31][32] - 公司已证明能够在就业和GDP增长之外实现增长 通过转换非项目客户、向现有客户销售额外服务、保持高保留率和并购等方式实现增长 [33] 问题: 季度初需求趋势 [35] - 从第一季度到第二季度初需求没有真正变化 各路由业务增长势头良好 [35] 问题: 客户基础改善的具体指标 [39] - 通过现有客户关系扩展的案例：西南部制造客户从制服租赁扩展到设施服务、急救与安全服务和消防服务 [41][42][43] 问题: 库存和制服注入 [44] - 租赁业务持续增长 资本使用包括为制服租赁业务注入服装 反映所有三个路由业务的增长 [46] 问题: 不同垂直领域客户行为变化 [49] - 各垂直领域没有真正看到行为变化 所有选择垂直领域都对增长有贡献 包括医疗保健、酒店、教育和州地方政府 [50] 问题: EPS指引范围较宽的原因 [51] - 指引范围允许公司进行长期投资 同时提高利润率 增量保持在25%-35%的理想范围内 [51][52] 问题: 关税驱动费用增长 [56] - 全球供应链是竞争优势 具有显著采购力和地理多样性 90%+产品有两个以上供应商 指引已考虑当前关税环境 [57][59] 问题: 非项目客户销售周期变化 [60] - 销售周期没有真正变化 公司继续投资未来 [60] 问题: 急救与安全业务毛利率下降原因 [64] - 主要是与去年相比存在挑战 业务投资包括路由能力、领导力储备、技术、销售资源和管理培训生 更多是时间问题 [65][66] 问题: 2026财年投资水平与2025财年比较 [67] - 更多是时间问题 去年第四季度开始加大投资 继续增加销售资源和路由能力 [69] 问题: 竞争环境变化和份额获取机会 [71] - 整体市场仍然非常竞争 新业务赢单主要来自非项目客户 而非竞争对手 巨大未开发市场机会 [72] 问题: 其他业务部门运营利润率疲软 [73] - 其他部门包括消防和设计集合业务 毛利率环比上升10个基点 同比下降30个基点 正在适当投资这些业务 [73] 问题: 制服直接销售业务疲软及未来趋势 [76] - 该业务具有战略意义 虽然只占收入26% 但可带来路由业务机会 可能因大型项目推出而波动 [77][79] 问题: 并购管道和多元化可能性 [80] - 并购对公司重要 管道看起来良好 主要关注当前业务 但始终评估机会 [81][82] 问题: 急救与安全业务投资后增长前景 [85] - 预计该业务将继续保持低两位数增长 正在明智地进行投资 [86][87] 问题: 投资时间安排和增量利润率 [89] - 568%的毛利率非常具有吸引力 将继续获得杠杆作用 业务组合一直具有吸引力 [89][90] 问题: 消防和安全业务扩张策略 [93] - 消防业务未来光明 积极进行并购和有机增长 几乎每个季度都有收购 [94][95] 问题: AI和技术投资机会 [96] - 技术投资是战略关键部分 专注于让客户更容易与公司开展业务 使员工更成功 包括myCintas、Smart Truck等计划 [98][99][100] 问题: 国际扩张考虑和myCintas门户进展 [102] - 国际扩张不是必需 美国加拿大有1600-1700万企业 仅服务100多万 机会巨大 myCintas门户是竞争壁垒 客户和员工都喜欢 [104][105][106] 问题: 签证要求变化对客户招聘影响 [109] - 关注移民政策 但没有看到实质性影响 客户中很少听到相关问题 [110] 问题: 其他业务SG&A投资水平 [111] - SG&A投资目前处于适当水平 预计不会大幅增加或减少 公司总体SG&A改善10个基点 [112] 问题: 经济变化对各业务关键指标影响 [115] - 业务表现良好 租赁业务持续改善 三个路由业务均表现高水平 制服直接销售业务第一季度对公司增长造成30个基点阻力 [116] 问题: 并购价格变化 [117] - 并购价格没有真正变化 预测出售时机具有挑战性 公司关系良好 声誉良好 [118] 问题: 关税对资本支出影响 [122] - 关税影响各业务 供应链组织表现出色 4%的资本支出目标预计将保持一致 [123]

Cintas (NasdaqGS:CTAS) Q1 2026 Earnings Call September 24, 2025 10:00 AM ET Company ParticipantsJim Rozakis - EVP and COOLuke McFadden - Equity Research AssociateJasper Bibb - VP Equity ResearchScott Garula - EVP and CFOStephanie Moore - SVP Equity ResearchJared Mattingley - VP, Treasurer, and Investor RelationsTodd Schneider - President and CEOJared Mattingley - VP, Treasurer and Investor RelationsScott Schneeberger - Managing DirectorKartik Mehta - Executive Managing Director and Director of ResearchAlex ...

公司收购与股权变动 - 公司拟以自有资金或自筹资金2.8亿元收购玖安投资持有的上海嘉乐20%股份 对应收购PE约为13X [1] - 交易完成后滁州米润持有上海嘉乐71.8480%股份 公司对上海嘉乐合计持股比例从69.4%提升至81.4% [1] - 预计25年第四季度带来业绩增厚 [1] - 控股股东及实际控制人提前终止减持计划 对市场产生激励作用 [2] 财务表现与预测 - 第三季度公司利润有望高增长 主要由于服装下半年收入端加速及箱包净利率提升 [3] - 调整25/26/27年收入预测至52.38/60.02/68.74亿元 原预测为55.33/63.14/71.42亿元 [5] - 调整25/26/27年归母净利润预测至4.28/5.73/6.92亿元 原预测为4.60/5.84/7.12亿元 [5] - 对应调整25/26/27年EPS至1.78/2.39/2.89元 原预测为1.92/2.44/2.97元 [5] - 2025年9月22日收盘价24.67元对应25/26/27年PE为14/10/9X [5] 业务发展驱动因素 - 2B箱包业务25年有望实现双位数增长 净利率存在修复空间 主要来自产能利用率修复和汇兑影响减弱 [4] - 2B业务核心优势来自印尼布局 驱动因素包括净利率修复、下游补库存、老客户份额提升及新客户拓展 [4] - 2C业务核心驱动在于小米业务分成模式变化带来的利润率提升 [4] - 收购上海嘉乐进入服装代工赛道 打开第二增长曲线且净利率存在修复空间 [4] - 公司对美国出口收入占比15% 全部由印尼出口 美国对印尼征收19%关税使印尼先发布局优势凸显 [4]

核心人事任命 - 核准李丽艳担任京东安联财险审计责任人 完善公司治理架构 [2] - 核准张李利担任广东分公司副总经理 强化区域业务管理 [2] - 李丽艳为资深审计专家 2009年获国际注册内部审计师资格 2012年加入公司全面负责内部审计工作 [5] - 张李利具有泛华保险运营管理经验 2022-2024年担任深圳营销服务部负责人 华南市场经验丰富 [5] 公司发展历程 - 前身为2003年安联保险集团在华设立的首家财产险公司（广州分公司） [5] - 2010年改建为独立法人子公司"安联财产保险（中国）有限公司" [5] - 2018年引入京东等新股东 注册资本从8.05亿元增至16.1亿元 [8] - 2019年更名为"京东安联财险" 业务进入提速期 [8] 经营业绩表现 - 保费收入从2018年12.41亿元增长至2024年63.96亿元 主要受益互联网场景业务协同 [8] - 2023年实现净利润0.30亿元 2024年净利润0.86亿元同比增长184.4% 创历史新高 [8] - 退货运费险2024年增长64.4% 但平均费率从1.07%降至0.36% 存在以价换量特征 [9] - 退货运费险连续三年亏损：2022年亏损1647万元 2023年亏损6256万元 2024年亏损1092万元 [9] 股权结构与治理 - 安联(中国)保险控股持股53.33%为第一大股东 京东系公司持股33%为第二大股东 [10] - 中原信达持股9.40% 深圳汇京通达持股4.27% 分别为第三、四大股东 [10] - 高管团队呈现年轻化特征 核心管理成员多为80后 近半数拥有外企任职经历 [6][7] - 形成"一正三副"管理格局：总经理梁海健（德勤/安永背景）及三位副总经理分管不同区域 [7] 业务布局特征 - 业务覆盖广东（含深圳）、上海、北京、四川四大核心区域 [6] - 退货运费险为战略支柱险种 深度依托京东生态场景优势 [9] - 总部位于广州 广东分公司为重要区域运营主体 [2][5]

[角色] 你是一名拥有10年投资银行从业经验的资深研究分析师，专门负责上市公司、行业研究。你擅长解读公司财报、行业动态、宏观市场，发现潜在的投资机会和风险。 [任务] 你需要仔细研读一份上市公司或者行业研究的电话会议记录，请阅读全文，一步一步思考，总结全文列出关键要点，不要错过任何信息，包括： * 纪要涉及的行业或者公司 * 纪要提到的核心观点和论据 * 其他重要但是可能被忽略的内容 如果没有相关内容，请跳过这一部分，进行其他的部分。 总结时要全面、详细、尽可能覆盖全部的内容、不遗漏重点,并根据上述方面对内容进行分组。 要引用原文数字数据和百分比变化,注意单位换算(billion=十亿,million=百万,thousand=千)。 [注意事项] 1) 使用中文,不要出现句号 2) 采用markdown格式 3) 不使用第一人称,以"公司"、"行业"代替 4) 只输出关于公司和行业的内容 5) 在每一个关键点后用[序号]形式引用原文档id 6) 一个[序号]只应该包含一个数字，不能包含多个，如果多个就用[序号][序号]分开写，不要写成 [序号-序号] 7) 每个关键要点后边的 [序号] 不要超过 3 个 Content: --------- <doc id='1'>QuidelOrtho (NasdaqGS:QDEL) 2025 Conference September 10, 2025 03:10 PM ET Speaker0 Go ahead and get started, I'm Katherine Schulte, I cover life sciences and diagnostics here at Baird. Very excited to have Quidel Ortho joining us today. From the company we have the CFO, Joe Buske. So Joe, thanks so much for joining us. I think we're gonna dive right into Q and A so if anyone has a question, feel free to send them to session3rwbear dot com and I will pass them along.</doc> <doc id='2'>So Joe, thought maybe we could just start at a high level. Can you just talk about key takeaways from the quarter and maybe how your strategic vision for the company is unfolding here? Speaker1 Sure. And by the way, thanks, Katherine. Thanks for having us to the conference. It's been great. And as far as that first question on highlights from Q2, I would say that we've now had two good quarters in a row to start off 2025 with good margin improvement of 400 plus basis point margin improvement over the prior year.</doc> <doc id='3'>I think we also showed that we've made some strategic decisions in line with what Brian and I said we were wanna do fifteen months ago when he started. And, examples of that would be we we announced that we're closing a very large manufacturing facility in Raritan, New Jersey, which is gonna provide some real nice operating margin improvement in a couple years. And we made the decision to pivot from Savannah development of molecular product to Lex, which is a business in UK that we're going to purchase once they get FDA approval for their first respiratory panel. And so again these decisions are just all around margin improvement and making the company more productive and more efficient. Again, things that Brian and I said we were gonna do last year when he when he started.</doc> <doc id='4'>I guess the last thing I'd mention is that the base business continues to grow in at the rate which we said it would grow, you know, in that sort of mid single digit growth for labs and immunohematology.</doc> <doc id='5'>Speaker0 Yeah, I want to get into Lexin a bit, but maybe starting on the lab side of the business. You know, to your point, recurring revenue growth remained solid to start the year. You know, where do you think you're winning in the clinical chemistry business? Speaker1 Yeah, the strategy with labs continues a strategy that was started probably about five or so years ago, and that is to focus on the small to mid size hospital and labs, which we define as our sweet spot. You know, we're doing quite well there. I would say the other strategy is to focus on leading with integrated analyzers that runs both routine chemistry and immunoassays. And, you know, that strategy continues to be the one that we're gonna employ and it's it's working quite well. And, you know, the growth in the labs business continues to be right where we said it would be in that mid single digit growth range.</doc> <doc id='6'>Speaker0 What about on the instrumentation side? You know, how's the current capital equipment environment? Speaker1 Yeah, I don't see a lot of impact of customers pausing on placing analyzers due to the macro. And I think it's mainly because the the value of the analyzers we're placing is much less than, say, an MRI or imaging piece of equipment that's, you know, millions and millions of dollars. I think I think our purchase the equipment purchases that our customers are making kind of fly below the radar to some extent. We also offer, like our competitors do, an alternative to to buying an instrument, and that is a reagent rental where we can place an analyzer at a customer location and charge them the cost of the box over the life of the contract in the form of a surcharge on the consumables. So that's a way of kind of getting around maybe CapEx limitations that a customer may have.</doc> <doc id='7'>Speaker0 And how important is the automation element to customers? You know, how has your integrated analyzer kind of helped in this environment? And I think it's around a third of your installed base now, so how do you think that will track over time? Speaker1 Yeah, for sure automation and the integrated analyzers are super important to our customers and to our strategy of growing the labs business. In fact, you look at the automation, or I should say the growth in the automation and installed base over the last several years, it's typically been in the high single digits and low double digits as indicative of the strategy working. You know, we continue to lead with that integrated analyzer which is going to drive more higher margin immunoassay revenue growth for us. And that's important because if you look at our business relative to where the market is, our mix of immunoassay and routine chemistry is inverted from where the overall market is. And so there's lots of room for us to grow that immunoassay side of the business.</doc> <doc id='8'>And in fact, if you look at our percentage of installed base that's integrated versus nonintegrated, if you go back to when Ortho Clinical Diagnostics went public in 2021, we were around 24% of the base was integrated, and now we're sitting at around 30% of that base, installed base, being integrated. So you can kind of get a feel for the pace of which we're moving and employing that strategy and you can also get a feel for how much room is left to run, how much we can run this strategy out. There's plenty of runway left.</doc> <doc id='9'>Speaker0 And in terms of that kind of immunoassay mix, I guess where do you see the biggest opportunities in the portfolio to keep driving that? Speaker1 Yeah, good question. I think that if you look at where the labs growth is, you know, in the more developed markets of The US and Western Europe, you'll see more, you know, low to mid single digit growth. But when you look in less developed areas like Latin America and Asia Pacific and Eastern Europe, you'll see more high single digits, sometimes low double digit growth. And so we I I look towards those lesser developed markets of Eastern Europe and Asia Pac as the areas where I think there's lots of opportunity for us to to grow that integrated analyzer base and grow that immunoassay business.</doc> <doc id='10'>Speaker0 And if we move on to molecular, you know, how does the planned Flex acquisition kind of expand your footprint there and maybe talk through the strategic rationale for pursuing that route instead of continuing with Savannah.</doc> <doc id='11'>Speaker1 Yeah, it was a really tough decision that we made back in June to pivot from developing Savannah to Lex. Savannah had been a product that Quidel had been working on prior to the combination with ortho for many years and it's it's it's a great product. Savannah, I think, has a lot of potential competitive advantages in the marketplace, but Lex also has some very distinct competitive advantages in the marketplace where we intend to sell it and those advantages I would say are focused on turnaround time, ease of use and cost. And so the decision was made to pivot to Lex primarily because if you look at the amount of time it would take to fill out the menu, the amount of cost it would take to fill out the menu, and the level of technical risk, which is much less in a product like Lex, we decided to discontinue Savannah and focus our resources on Lex because again, we think we can get that menu filled out much faster and for much less cost and a lot less risk. And so we believe that the first panel which was submitted to the FDA which is a respiratory panel in June, we believe that we will get approval for that panel sometime later this year.</doc> <doc id='12'>Speaker0 And maybe what's the timeline for menu expansion there into other respiratory or women's health applications? Just curious, you know, how much there is an opportunity outside of that initial panel.</doc> <doc id='13'>Speaker1 Yeah, there's lots of opportunity to fill out that menu. I think first we'll focus on RSV and strep being added to the panel and then women's health and STI will be next. More to come on specific timelines but yeah, there's plenty of opportunity to fill up that menu and expand.</doc> <doc id='14'>Speaker0 And how do you think about, you know, the overlap with kind of the rest of your portfolio? Is there any potential cannibalization for Sofia? Speaker1 The good news is is that the Lex product can be commercialized through the existing sales force. So there's no need to add any resources to commercialize Lex as we move into early twenty six. They're based on the customer research that we've done, the KOLs we've talked to, we believe there's plenty of room for both a rapid antigen test like Sofia and a molecular product like Lex. And there is some some overlap but I would say it's not not significant at all. It's probably, you know, 10% or less of of overlap and and even that amount of overlap is not overly concerning for us because if there are customers who'd rather use Lex rather than Savannah, the Lex margins are higher.</doc> <doc id='15'>And so that would be some minor amounts of cannibalization that I'd probably welcome from a margin perspective.</doc> <doc id='16'>Speaker0 And you've talked about kind of reinvesting some of your Savannah dollars into Lex, you know, where are those investments mainly concentrated this year and kinda what additional steps are you taking to prepare for that kind of limited commercial launch in the first half of next year? Speaker1 Yeah, we're definitely excited about getting approval on that first panel later this year so we can start a limited commercialization in this first and second quarter twenty six respiratory season. As I said a minute ago, really no need for any additional commercial resources. We've got everything we need. Being the leader in respiratory testing in The US, we've got all the commercial resources that we need to sell that product. I guess the most near term investments might be in the form of not too significant CapEx that will be needed to increase the manufacturing capacity for Lex.</doc> <doc id='17'>There is a line that the company has in The UK right now but will need an additional line either somewhere in The UK again or in The US. Haven't decided that yet but that will be something that will stand up pretty early in '26 so that we can hit the late in the '26, early twenty seven respiratory season with a much more fulsome rollout and commercialization.</doc> <doc id='18'>Speaker0 Okay. And then on point of care, you you lowered the 2025 outlook for COVID revenue coming out of the second quarter. Can you just remind us of the seasonality baked in for the third and fourth quarter and maybe just given the trends that you've seen so far this year, you know, how you think about forecasting, you know, endemic COVID revenues longer term? Speaker1 Yeah. COVID's been been quite the ride. And I I know that there's been a lot of focus on the on the decline of the COVID revenue over the last several years, but I do believe that as a headline conclusion, we've digested most of that decline. When you think about where we were in '21 and '22 with a billion 4 of COVID revenue that's dropped to 400,000,000 and then a 185,000,000 last year, you know, the guidance this year is for 70 to a 100. And if you just pick the midpoint of of that, somewhere you in the mid eighties, I think that's a realistic, very realistic point of of where where the declines end.</doc> <doc id='19'>And, you know, and I can say that with with some confidence because all of the the government order revenue is is gone and the retail business is is fairly small at this point. There's not a whole lot lot left. So most of what's left is the professional use space revenue which has proven to be somewhat consistent and durable. And so we do think that that, you know, call it that midpoint of the 70 to a 100 is probably a good place to think that not only we're gonna end up this year, but where we're gonna go for the next next several years with COVID revenue. So I think all of these views of revenue of ex COVID that we've done for the past couple years, think we're we're really getting to the end of that, which is great news, I know, the buy side and sell side.</doc> <doc id='20'>Speaker0 Yep. Absolutely. Maybe any thoughts on the upcoming flu season? Are there any clues from the Southern Hemisphere around, you know, what this upcoming season could look like relative to historical trends? Speaker1 Yeah. The flu season in the Southern Hemisphere is always a good data point for us and that flu season has turned out to be one that I would define as more typical or average. And so that's good because that's what we've said all along this year is that our guidance for flu revenue is gonna be a typical or average season. And we define that as flu season in terms of volume, 50 to 55,000,000 tests, and the combo test mix being greater than 50% and steady market share. So the new model that we've gone to to project the flu revenue that we went to in '24 has proven out to be a good one.</doc> <doc id='21'>You know, we very close, almost I would say spot on to what we guided the street to for the first half of the year for flu revenue. And so we have a lot of confidence that where we are for the second half of this year is going to be pretty close as well. And and, you know, what we're seeing is that the the patterns for the flu season are getting back to more predictable pre pandemic patterns. The the level of testing is up versus pre pandemic mainly because of the combo test, and we think that combo test is pretty durable given that it's been over 50% of our flu revenue now for two plus years. And so, you know, I think that flu season is, the flu season revenue is getting a little more predictable.</doc> <doc id='22'>So we feel good about where the guidance is for the second half of the year.</doc> <doc id='23'>Speaker0 Yeah. Maybe shifting to transfusion medicine, you know, how should we think about that business following the U. Donor screening wind down and, you know, what's your view on the growth outlook there? Speaker1 Yeah, so as a reminder, the transfusion medicine business unit for us is comprised of the donor screening business, which is primarily the business of screening for infectious disease in the blood supply donations. And we decided to shut down, wind down that business last year because it is a small market, It's lower growth and it's it's got lower margins compared to the rest of our businesses. So we decided to wind it down last year. And, you know, last year we did about a 120,000,000 of revenue. This year it'll be probably 40 to 50,000,000 of revenue.</doc> <doc id='24'>And this business will be fully wound down in early twenty six. And so again, that revenue headwind of the donor screening wind down, which we've had all year, which is down about 40% in the first half of the year, that headwind will go away in the first half of next year and we won't be dealing with that anymore. And the top line revenue growth will be made up more of the base business, which we see as a mid single digit growth business. The other business within transfusion medicine is immunohematology, and that's a business that we really like. That business is global.</doc> <doc id='25'>We're the global number one in terms of market share with that business and we do intend to continue to invest in that business going forward.</doc> <doc id='26'>Speaker0 Yeah. Okay. And maybe on China, there's been a lot of noise there for diagnostics companies, particularly this quarter. It sounds like you've been relatively insulated from some of the unbundling and VBP headwinds that</doc> <doc id='27'>others are seeing. Is that right? And are there any parts of your business that are seeing pressure there? Speaker1 I was waiting for the China questions. I knew they were coming. The we spent a lot of time on this on our last earnings call. Brian, I think, did a great job of of talking about why our business is different from others in our space in in China. And I know a lot of folks like to paint a broad brush with with the China risk, but our business is different, and here's why.</doc> <doc id='28'>First of all, we use a dry slide technology on our lab side, which none

好的，我将为您总结American Eagle Outfitters (AEO) 2026财年第二季度财报电话会议的关键要点。 财务数据和关键指标变化 - 第二季度总营收12.8亿美元，同比下降1%，为公司历史上第二高的第二季度营收 [5][21] - 可比销售额下降1%，但客流量在所有品牌和渠道均实现正增长 [5][21] - 毛利润5亿美元，毛利率38.9%，较去年同期的38.6%有所改善 [22] - 营业收入1.03亿美元，同比增长2%，营业利润率8%高于去年同期的7.8% [7][24] - 摊薄后每股收益同比增长15% [7] - 销售和管理费用(SG&A)下降1%至3.42亿美元，占销售额比例与去年持平 [6][23] - 期末库存成本增长8%，库存数量增长3%，库存成本增加主要受关税影响 [24][99] 各条业务线数据和关键指标变化 - Aerie业务实现3%的可比增长，创下第二季度营收纪录，内衣、软装、睡衣和Offline运动服系列需求积极 [5][14] - American Eagle可比销售额下降，但需求在整个季度逐步改善，关键品类出现好转 [16] - 女装牛仔裤、上衣和连衣裙表现强劲，男装在图形T恤、针织上衣和牛仔裤等关键分类中也呈现良好趋势 [16] - 内衣类别约占Aerie业务的三分之一，市场份额有所提升 [54][66] - 短裤品类在所有品牌中仍然面临挑战 [14][42][71] 各个市场数据和关键指标变化 - 营销活动在美国所有县都带来了新客户 acquisition，势头是全国性的 [33][58] - 数字渠道平均单价(AUR)持平，而整体AUR下降中个位数百分比 [46] - 8月份可比销售额转为正增长，整个月保持增长势头 [11][22] 公司战略和发展方向和行业竞争 - 公司正采取行动重新点燃业绩，包括跨品牌产品计划、新营销活动和更强运营纪律 [5] - 供应链优化是重点计划组成部分，正在创造更高效率和速度 [8] - 通过调整原产国、与供应商成本谈判、优化运费等方式积极应对关税影响 [48][73] - 资本配置平衡长期增长投资与股东回报，年初至今通过股息和股票回购向股东返还2.76亿美元 [9][10] - 计划今年开设约30家Aerie和Offline门店，改造40-50家AE门店采用现代门店设计，同时预计关闭35-40家American Eagle门店 [26][89] 管理层对经营环境和未来前景的评论 - 消费背景动态变化，但公司专注于控制可控因素，提供领先客户体验同时保持成本纪律 [4] - 秋季开局良好，产品线实力和近期营销活动成功推动业务 [11] - 与Sydney Sweeney和Travis Kelce的合作活动创造了巨大能量和热议，Sydney签名牛仔裤一周内售罄，部分产品一天内售罄 [17][18] - 自活动启动以来，客户数量增加超过70万，活动共产生400亿次展示 [19] - 关税影响将在下半年开始显现，第三季度预计约2000万美元，第四季度预计4000万至5000万美元 [28][47] 其他重要信息 - 第二季度资本支出7100万美元，年初至今支出1.33亿美元，全年资本支出预期仍为约2.75亿美元 [25] - 公司完成2亿美元加速股票回购计划，年初至今共返还2.31亿美元用于回购，减少流通股2000万股(约10%) [10][25] - 期末现金1.27亿美元，总流动性约4亿美元 [26] - 第三季度至今可比销售额增长中个位数百分比，包括劳动节周末的强劲表现 [27] - 第三季度营业收入预期在9500万至1亿美元之间，第四季度营业利润预期在1.25亿至1.3亿美元之间 [28] 问答环节所有提问和回答 问题: 如何保持营销活动势头以及新客户购买行为 [31] - Sydney Sweeney活动旨在实现品牌和业务重置，六周内创造了前所未有的新客户获取，来自美国每个县 [33] - 客户购买行为跨越所有品牌，推动网站流量，劳动节创历史纪录 [36] - 牛仔裤品类表现优异，吸引不同体型和年龄组的新客户，内衣品类回归，男装业务加速改善 [38][39] 问题: 产品组合从上半年到现在的演变 [40] - Aerie在抓绒等核心品类改善，内衣从第一季度开始好转，短裤是季节性挑战品类 [41][42] - American Eagle业务季度内逐步改善，现在牛仔裤、上衣、毛衣和抓绒等应季品类表现良好 [43] 问题: 可比销售指标和关税细节 [46] - 第二季度AUR下降中个位数百分比，数字渠道AUR持平 [46] - 关税缓解措施包括调整原产国、成本谈判、优化运费和一些定价策略，定价不是主要缓解策略 [48] - 第三季度至今AUR略有上升，低个位数增长 [50] 问题: 内衣销售占比和现有客户表现 [53] - 内衣约占业务的三分之一，巴黎系列推出时机恰当，蕾丝元素奏效 [54][55] - 新客户获取在全国范围内增长，Travis Kelce活动在劳动节周末主导男装业务 [58][61] 问题: 产品类别表现和定价展望 [64] - 牛仔裤AUR良好上升，平衡价格点策略 [65] - 内衣市场份额提升，软装品类表现良好，短裤是共同挑战品类 [66][71] - 定价将是持续缓解关税影响的工具之一，但非主要策略 [73] 问题: 下半年毛利率和营销活动持续性 [75] - 第四季度关税影响更大，促销活动假设嵌入预期，数字销售增长可能带来配送成本压力 [77][79] - Sydney Sweeney活动将持续全年，Travis Kelce将有第二次产品投放 [82] 问题: 关税影响和男装业务进展 [85] - 未缓解的关税影响约1.8亿美元，团队成功降至约7000万美元 [86] - 2026年全年预期影响约1.25亿至1.5亿美元，正在寻找各种抵消方式 [87] - 男装业务改善，新商家带来新想法，牛仔裤、上衣和 bottoms 表现上升 [91][92] 问题: 营销活动持续时间和广告支出 [94] - 两个营销活动都将持续至年底，Travis Kelce将有第二次产品投放 [94][95] - 第三季度SG&A预计增长高个位数，主要因广告支出增加，第四季度广告支出预计低个位数增长 [97] 问题: 库存计划 [99] - 库存增长主要受关税影响，单位增长与销售趋势基本一致 [99] - 正在追加工人牛仔裤等长生命周期商品，库存状况良好 [100] 问题: SG&A管理 [103] - SG&A改善得益于多年费用管理举措，补偿成本因重组举措下降 [104] - 长期目标是在3%-5%收入增长下保持SG&A持平或杠杆化 [105] - 激励性补偿今年下降，明年将重新评估 [108] 问题: 库存增加原因和未来合作计划 [112] - 库存增加主要因关税影响，少量因关税时机提前备货 [113] - Travis Kelce产品销售强劲，高价位产品表现良好，Sydney Sweeney有更多计划正在筹备中 [116][117] - 泳装业务按计划执行，售罄时尚款式，季末清货较少 [118][119]

财务业绩 - 2025年上半年营收约3.4亿元，同比增长40.19% [2] - 2025年上半年净利润约5493万元，同比增长16.52% [2] - 三大业务板块均实现增长 [2] 产能建设进展 - 东莞基地已于2024年6月投产 [2] - 昆山基地计划2025年底达到预计可使用状态，已完成主体基建建设 [2] - 泰国基地预计2025年底基本完成厂房建设，2026年上半年逐步投产 [2] 业务发展态势 - 车用高频高速连接器发展势头良好 [2] - 受益于新能源汽车渗透率提升 [2] - 受益于智能驾驶普及率提升 [2] 会议基本信息 - 会议形式为2025年半年度网上业绩说明会 [2] - 会议时间：2025年9月1日15:00-16:30 [2] - 会议平台："互动易"网站"云访谈"栏目 [2] - 参会高管：董事长李文化、独立董事谭旭明、董事会秘书刘雨田、财务总监戴喜燕 [2]

财务数据和关键指标变化 - 收入增长6%至1 343亿美元 主要受冒险体验和快速改善的跳伞业务推动 [4][11] - 基础EBITDA增长34%至1 930万美元 为疫情以来最强财务表现 [4][11] - 基础税后净利润(商誉减值前)为210万美元 为疫情以来首次实现基础盈利 [4][12] - 现金状况改善280万美元 [4] - 经营现金流增长53%至1 710万美元 [21] - 基础自由现金流增加630万美元 [21] - 维护性资本支出增加80万美元至810万美元 [22] - 法定税后亏损100万美元 主要因Wildbush Luxury商誉减值310万美元 [12] 各条业务线数据和关键指标变化 - 跳伞业务收入增长5% EBITDA增长27% 主要受销量提升和站点效率改善推动 [13] - 澳大利亚跳伞串联跳伞量增长9% [13] - 新西兰跳伞串联跳伞量增长10% [14] - 平均客户收入增长2% [15] - 冒险体验业务收入增长7% EBITDA增长14% [17] - Reef Unlimited收入增长7% 平均客户收入增长6% [17] - Treetops收入增长12% 平均客户收入增长10% [18] - Wildbush Luxury财务表现改善 但受澳大利亚人出境游影响 [19] 各个市场数据和关键指标变化 - 澳大利亚和新西兰国内及国际旅游业整体改善 [9] - 英国和欧洲大陆客户数量同比增长超过60% [31] - 中国市场恢复至疫情前70%水平 [46] - 关键学校假期期间交易强劲 12月、1月和4月表现超预期 [5] - 5月和6月因天气原因表现令人失望 [5] 公司战略和发展方向和行业竞争 - 战略围绕四个支柱:业务绩效改善、维持交易势头、未来增长和投资组合质量 [4][26] - 重点改善澳大利亚串联跳伞收益和自由现金流生成 [26] - 有机增长为重点 已确定超过10个树顶项目站点 [28][29] - 推出两岛探险之旅(菲茨罗伊岛和绿岛) 为独家许可产品 [29] - 积极寻找户外冒险和海洋板块的附加收购机会 [29] - 与澳大利亚旅游局、新西兰旅游局等机构合作利用市场动态 [9] - 成本效率计划目标实现200万美元年化节省 [32] 管理层对经营环境和未来前景的评论 - 对澳大利亚和新西兰游客过夜旅行和过夜游客支出增长前景充满信心 [9] - 7月交易势头延续FY2025的强劲表现 超出预算和内部预测 [30] - 澳大利亚即将举行的系列活动为业务表现提供信心 [32] - 利率削减和趋势改善使对国内前景更加乐观 [38] - 中国黄金周和农历新年前景看好 [44][46] 其他重要信息 - 董事会宣布每股0 25澳元完全免税股息 为2018年以来首次派息 [4][32] - 现金余额1 110万澳元 净债务1 090万澳元 净债务与EBITDA比率为0 6 [19] - 未动用资金1 420万美元可用于增长计划 [20] - 税收损失结转5 590万澳元可增强未来现金流 [20] - 税收抵免余额930万澳元将用于支付股息 [20] - 实施市场股票回购计划 [6][24] - 评估处置过剩和非绩效资产机会 [6][74] 问答环节所有提问和回答 问题: 信心驱动因素及国际/国内增长前景 [36] - 信心来自运营利润率改善、年度化成本节省300万美元、直接预订比例提高、国际访问量宏观环境改善、国内前景因利率削减而改善 国际和国内市场都将推动增长 [37][38][39] 问题: 新西兰跳伞业务量调配能力及中国新年展望 [41][42] - 具备跨站点转移客户和教练的能力 对新西兰中国新年期间表现充满信心 因皇后镇是必游目的地 [42][44] 问题: 黄金周新西兰前景 [46] - 中国市场持续改善 两国恢复至70%水平 期待黄金周表现 [46] 问题: 热带北昆士兰市场动态和产品供应 [48] - 对地区投资感到兴奋 新产品如两岛之旅具有差异化优势 市场反应积极 [49][50][51] 问题: 董事会股息决策 rationale [57] - 基于FY2025交易表现和FY2026及以后展望 有信心能够负担 [58][59] 问题: 跳伞业务恢复至2 500万美元目标的可行性 [61] - 仍然认为可行 虽业务结构变化 但通过提高单客收入、成本优化和国际市场回归 保持信心 [62][63] 问题: 资本支出展望 [64] - 维护性资本支出由飞机和船只计划维护驱动 可能波动 增长性资本支出将利用债务设施 [65][66][67] 问题: Aquarius II收购回报期 [71] - 四年的回报期仍然成立 船只在使用中表现超出预期 [71][72] 问题: 资产处置规模 [73] - 主要涉及过剩飞机(如3架不再在澳服务的空中国王飞机)和杂项物业 非大规模处置 [74] 问题: 天气影响程度 [75] - 未量化但认为若无天气影响 表现会远优于FY2024 特别是5-6月份 [76][77]

财务数据和关键指标变化 - 总客运量同比增长13.7%至近2100万人次 从第一季度的7%增长或9%增长(不包括纳塔尔)加速 [8] - 总收入(不包括IFRIC 12)同比增长18.9% 超过客运量增长 [17] - 每乘客收入从去年的20.1美元上升4.5%至21美元 [17] - 调整后EBITDA(不包括IFRIC 12)达到1.69亿美元 同比增长23% [21] - 调整后EBITDA利润率(不包括IFRIC 12)同比上升1.4个百分点至38.6% [22] - 总流动性头寸为5.95亿美元 较2024年底的5.26亿美元增长13% [23] - 总债务为11亿美元 净债务从2024年12月的7.18亿美元降至6.43亿美元 [24] - 净杠杆率改善至创纪录的1倍 得益于净债务减少和调整后EBITDA水平增强 [24] 各条业务线数据和关键指标变化 - 航空收入增长15.1% 主要受阿根廷强劲表现推动 除厄瓜多尔外所有国家均有积极贡献 [18] - 商业收入同比增长22% 远高于13.7%的客运量增长 受更高货运收入和停车设施、贵宾休息室、免税店及其他乘客相关服务的稳健表现推动 [18] - 货运收入同比增长30% 由阿根廷、巴西和乌拉圭引领 [14] - 阿根廷实施的新货运商业模式按计划交付 乌拉圭快递部门关税上调带来稳健提升 巴西受益于进口药品量增加和国内货运平均票面价值提高 [15] 各个市场数据和关键指标变化 - 阿根廷整体客运量增长加速至17% 国内客运量增长16% 国际客运量增长近19% [9] - 意大利客运量增长9% 达到第二季度历史记录 国际客运量(占总量的81%)增长9% 国内客运量增长11% [10] - 巴西客运量同比增长15% 国内客运量增长近14% 中转乘客增长15% 国际客运量增长超过41% [10] - 乌拉圭客运量增长近9% 也创下第二季度记录 [11] - 亚美尼亚客运量增长8% 受多家新航空公司入驻推动 [12] - 厄瓜多尔客运量基本持平 总乘客下降0.5% [13] 公司战略和发展方向和行业竞争 - 继续专注于提升非航空收入 在阿根廷塞萨尔机场开设新的免税到达区 面积从700平方米扩大至1100平方米 [26] - 巴西巴西利亚机场购物中心建设进展中 计划2026年4月开业 同时推动整个组合的餐饮、零售和服务产品增长 [27] - 战略上推进特许权项目 阿根廷推进AA2000特许权重新平衡流程 意大利4月获得托斯卡纳地区对佛罗伦萨机场总体规划的环境批准 亚美尼亚继续推进埃里温机场扩建的资本支出计划审批 [28] - 在新业务方面 等待黑山政府的官方决议 并积极寻求拉丁美洲、伊拉克、安哥拉及其他并购机会 [29] 管理层对经营环境和未来前景的评论 - 阿根廷表现出色 创下第二季度历史记录 国内和国际旅行均实现两位数增长 [5] - 意大利、乌拉圭和亚美尼亚也创下第二季度历史记录 [6] - 阿根廷7月国内和国际客运量分别增长10%和13% 意大利7月国内和国际客运量分别增长8%和6% [9][10] - 乌拉圭7月整体客运量同比下降6% 主要受JetSmart取消蒙得维的亚-布宜诺斯艾利斯航线及多日恶劣天气导致航班取消影响 [12] - 厄瓜多尔国内客运量微升 国际客运量下降 受美国业务减少影响 高机场水平和仍具挑战性的安全环境继续影响旅行 [13] - 预计阿根廷的积极客运势头将持续 意大利和罗马尼亚预计迎来强劲夏季旺季 [29] 其他重要信息 - 阿根廷子公司AA2000最近批准了1.5亿美元的股息分配 其中1.275亿美元将支付给CAAP [23] - 所有运营子公司报告了截至当时的正向经营活动现金流 除厄瓜多尔外 因一次性年度特许权费支付(每年1月到期和支付) [23] - 用于融资活动的现金反映了阿根廷和厄瓜多尔的债务偿还以及支付给子公司非控股权益的股息 [23] 问答环节所有的提问和回答 问题: 阿根廷费率调整讨论的下一步骤是什么 以及对于前CCR机场出售的资产是否仍感兴趣 是否会单独投标或考虑与合作伙伴分工 [31][32] - 公司正在关注该资产 这是一个典型的并购过程 受保密协议等约束 目前可以说的是公司正在关注该资产 这是一个有趣的机会 将随着过程进展向市场更新 [33] - 关于阿根廷 技术团队之间的对话正在进行中 从未中断 对话包括经济平衡的重新调整、系统投资要求等方面 5月中旬有新交通部长上任 公司与所有当局保持密切接触 相信正在取得良好进展 并将随着具体步骤向市场更新 [34][35]